G
Gary R. Lichtenstein
Researcher at University of Pennsylvania
Publications - 532
Citations - 32203
Gary R. Lichtenstein is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 73, co-authored 499 publications receiving 29495 citations. Previous affiliations of Gary R. Lichtenstein include Lahey Hospital & Medical Center & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Management of Crohn's Disease in Adults
Gary R. Lichtenstein,Stephen B. Hanauer,Stephen B. Hanauer,Stephen B. Hanauer,William J. Sandborn,William J. Sandborn,William J. Sandborn +6 more
TL;DR: These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and may be updated with pertinent scientific developments at a later time.
Journal ArticleDOI
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Paul Rutgeerts,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Stephen B. Hanauer +10 more
TL;DR: The scheduled infliximab groups, particularly the 10 mg/kg group, had better CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ) responses than those in the episodic group.
Journal ArticleDOI
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Gary R. Lichtenstein,Brian G. Feagan,Russell D. Cohen,Bruce Salzberg,Robert H. Diamond,Donny M. Chen,Michelle L. Pritchard,William J. Sandborn +7 more
TL;DR: Although the unadjusted analysis showed an increased risk for infection with infliximab use, multivariate logistic regression analysis suggested that inflIXimab was not an independent predictor of serious infections.